Brazil Acne Therapeutics Market Analysis

Brazil Acne Therapeutics Market Executive Analysis

The Brazil acne therapeutics market size is at around $251 Mn in 2022 and is projected to reach $454 Mn in 2030, exhibiting a CAGR of 7.7% during the forecast period. Brazil, which has a population of more than 200 Mn, is the largest nation in South America. Brazil has grown to be the second-largest pharmaceutical market worldwide. Nearly $26.15 Bn was spent on healthcare in 2022, with $11.94 Bn, or more than 45 %, going toward inpatient and outpatient hospital treatment. Brazil has a supplementary private sector used by about 30% of the population in addition to a universal state health service. Despite having on average lower incomes, older people in Brazil are usually more likely than younger ones to have a private health plan. Healthcare spending is disproportionately concentrated in the top two consumption quartiles, but the ratios of out-of-pocket expenses to family spending are comparable for those with public coverage (9.4%) and private coverage (10.4%). Older adults who use the public sector have slightly higher healthcare utilization appointments) and more than four times higher healthcare costs per doctor visit.

Acne vulgaris, a prevalent adolescent skin condition marked by comedones, papules, pustules, cysts, nodules, and rarely scars, is a chronic inflammatory condition of the pilosebaceous follicles. Acne impacts people of all ages, both genders, and various ethnic backgrounds in Brazil, but it is most common in the first three decades of life and accounts for 14% of dermatological consultations. Acne affects almost every part of a person's life, including their social, professional, and academic spheres, and it is not just an aesthetic inconvenience. Numerous psychosocial abnormalities, such as melancholy, suicidality, anxiety, psychosomatic symptoms, humiliation, and social inhibition, have been linked to acne, according to studies.

The severity of the condition, as determined by various gradings, influences the current treatment suggestions for acne in Brazil. Skin barrier alteration is linked to systemic and topical drugs like retinoids, topical antibiotics, and benzoyl peroxide, which may also cause skin dryness and irritation in some patients. These adverse effects might make it harder for patients to stick with their treatments, which would harm their chances of getting better. To reduce skin irritation, nonprescription acne medications and hygiene products like non-comedogenic cleansers and moisturizers have been effective and are gaining popularity in Brazil. Adult women with facial acne breakouts frequently have dry skin that is prone to irritation. They might benefit from non-prescription acne treatments that are specially formulated for them, such as cleansers and creams that address their condition.

Market Dynamics

Market Growth Drivers

In Brazil, the prevalence of acne is rising as a result of factors like changing dietary practices, lifestyle decisions, and pollution. As a result, there is a growing demand for acne therapeutics in Brazil. More people have access to monetary resources that they can use to invest in their health and well-being as the Brazilian economy continues to expand. As people strive to keep clear, healthy-looking skin, this may increase the demand for Brazil's acne therapeutics market.

Market Restraints

When it comes to acne treatments, some individuals may be price sensitive. This might slow the Brazil acne therapeutics market's expansion for costly therapies. Brazil's regulatory approval procedure for new acne therapeutics can be lengthy and expensive, which deters investment in the creation of new medications. This may restrict the market's access to cutting-edge and novel therapies in Brazil.

Competitive Landscape

Key Players

• Ache (BRA)
• Europharma (BRA)
• Neo Quimica (BRA)
• Mantecorp Farmasa (BRA)
• EMS Pharma (BRA)
• Teva Pharmaceuticals
• L'Oréal
• Sun Pharmaceuticals
• Johnson & Johnson
• Abbvie

Healthcare Policies and Regulatory Landscape

The Brazilian National Health System (SUS) includes the Brazilian Health Regulatory Agency (Anvisa), an autarchy connected to the Ministry of Health that serves as the administrator of the SNVS, or Brazilian Health Regulatory System, which is implemented across the entire country. The main objective of ANVISA is to safeguard and advance public health by conducting health monitoring of goods and services, including procedures, components, and technological advancements that could be harmful to consumers' health. The goal of ANVISA is to establish a flexible, contemporary, open, and domestic and international benchmark in health monitoring and regulation in order to gain legitimacy in society as a fundamental component of the Brazilian Unified Health System. The purpose of ANVISA is to "protect, promote, and intervene in the risks associated with the production and use of goods subject to health surveillance.

The licensing of pharmaceutical labs and other businesses involved in the pharmaceutical production process is the responsibility of ANVISA. Additionally, the organization is in charge of creating rules that apply to clinical trials (in terms of drug Chemistry, Manufacturing, and Control (CMC) and subject safety). ANVISA collaborates with the Chamber of medication Market Regulation (CMED) to control medication pricing, along with the Health Ministry and other ministries that are members of the organization.